D. Boral Capital Reiterates “Buy” Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research note issued on Monday,Benzinga reports. They currently have a $15.00 price objective on the stock. D. Boral Capital’s price objective points to a potential upside of 118.02% from the company’s current price.

COYA has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, November 11th. Chardan Capital restated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Thursday, February 6th.

Coya Therapeutics Trading Up 9.4 %

Shares of COYA opened at $6.88 on Monday. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.69. The firm has a fifty day moving average price of $6.20 and a 200-day moving average price of $6.46. The firm has a market capitalization of $114.94 million, a P/E ratio of -10.58 and a beta of 0.31.

Institutional Investors Weigh In On Coya Therapeutics

Hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC grew its stake in Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after purchasing an additional 4,777 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Coya Therapeutics in the 4th quarter valued at about $59,000. Jane Street Group LLC purchased a new position in shares of Coya Therapeutics in the 4th quarter worth approximately $74,000. Northern Trust Corp raised its stake in shares of Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after acquiring an additional 3,099 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Coya Therapeutics during the fourth quarter valued at approximately $401,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.